What we use actinium for
Where does it go, and why this element?
Cancer medicine and research. Actinium-225 is in clinical trials of drugs for prostate cancer, neuroendocrine tumors and gliomas1. Actinium-227 is the parent of radium-223, the active part of an approved drug for prostate cancer.
Last updated 14 October 2026.
Where it goes
No source gives the share of actinium that goes to each use. Actinium-225 and actinium-227 have different uses.
Actinium-225. A 2021 review in the Journal of Nuclear Medicine states that most actinium-225 goes into radiopharmaceuticals, for preclinical work and for clinical studies1. A radiopharmaceutical is a drug that carries a radioactive atom to a target in the body. Actinium-225 is also the source of bismuth-213, another isotope for the same kind of therapy1.
No drug with actinium-225 had approval in the sources that we read. Several were in trials. In 2024, Bristol Myers Squibb reported a Phase 3 trial of RYZ101, a drug with actinium-225, for neuroendocrine tumors of the gut and pancreas2. In July 2025 Novartis started a Phase 3 trial of actinium-225-PSMA-617 for advanced prostate cancer3.
Actinium-227. Two isotopes for therapy come from actinium-227: thorium-227 and radium-2231. Radium-223 is the active part of Xofigo, a drug from Bayer for prostate cancer that has spread to the bones1. The US Food and Drug Administration approved it in 20134. Actinium-227 was also used in actinium-beryllium neutron sources, and some of it is now recovered from old sources1.
Why this element
Actinium-225 emits alpha particles. The DOE writes that their energy is so high that it can break bonds in DNA, and that this damage can kill cancer cells5. One actinium-225 atom and its decay products release four alpha particles, and its half-life is 9.92 days1.
The DOE writes that a half-life of about 10 days suits some cancer treatments. It limits how much builds up in the body, but gives doctors time to prepare and give the drug5.
Chemists attach the actinium atom to a molecule that binds to cancer cells. In 2016 doctors in Heidelberg, Germany, reported on two patients who received actinium-225 on PSMA-617, a molecule that binds to prostate cancer cells6. The side effects are in the impact chapter.
What could replace it
Other alpha emitters can do the same kind of work. The 2021 review lists the ones in clinical use: thorium-227 and radium-223, actinium-225, astatine-211, and lead-212 with bismuth-2121. Several have supply problems of their own:
- Astatine-211 is perhaps the easiest to produce, but few accelerators can make it1.
- Bismuth-213 comes from actinium-225, so it does not remove the need for actinium. The review states that the limited availability and high cost of generators hamper studies1.
- Lead-212 generators from the DOE were sufficient only for preclinical work in 20211.
Drugs with lutetium-177, a beta emitter, are another option for prostate cancer, but they do not help all patients. The Heidelberg team wrote that about 30% of patients do not respond to lutetium-177 drugs for prostate cancer6.
We found no source that compares the cost of a treatment with each isotope.
Where demand is going
All figures here are forecasts or estimates by producers, their partners and one consultant. The 2021 review states that for most of these isotopes, demand is much larger than supply1.
- In 2018 the DOE wrote that demand could rise to more than 50,000 millicuries (50 curies) a year if the FDA approves several drugs. The production of that time could make 2 to 4% of that5.
- In 2022 DOE staff cited a DOE workshop of 2008. It projected demand of hundreds of curies a year, if several actinium-225 and bismuth-213 drugs are approved7. The staff gave a dose of 160 to 640 microcuries per patient7.
- In 2019 TerraPower and its partners spoke about the thorium-229 from Oak Ridge. They said that it could give 100 times more doses a year than the 4,000 available then8.
- In 2023 Richard Zimmermann, a consultant to the industry, estimated world capacity for actinium-225 in 2032 at well above 25 terabecquerels (670 curies) a year. He wrote that this should be enough for at least 2 million patient doses a year9. He wrote that the first actinium-225 drug might reach the market by 20289.
Sources
- 1
Radchenko V. et al., Journal of Nuclear Medicine 62(11), 2021. Production and Supply of α-Particle–Emitting Radionuclides for Targeted α-Therapy , Sections 227Th/223Ra and 225Ac/213Bi.
Production routes for actinium-225 and actinium-227, thorium-229 stocks by holder, world output of actinium-225, uses and supply limits.
-
Currently, most 225 Ac is used in the form of 225 Ac-labeled radiopharmaceuticals ( 43 ), both for preclinical development and for clinical studies mainly focusing on the treatment of prostate cancer, neuroendocrine tumors, and gliomas
-
It can be used for TAT radiopharmaceuticals or as a source of 213 Bi (t ½ , 45.61 min), which also can be applied in TAT ( 19 ).
-
Starting from 227 Ac (half-life [t ½ ], 21.77 y), 2 nuclides for TAT applications can be extracted: 227 Th (t ½ , 18.7 d) and 223 Ra (t ½ , 11.43 d)
-
223 Ra in its ionic form is clinically used as Xofigo in the treatment of bone metastatic prostate cancer ( 18 )
-
the recovery of 227 Ac from legacy actinium-beryllium neutron sources
-
with a t ½ of 9.92 d and a net emission of 4 α-particles in the decay chain
-
candidates that are currently in clinical practice ( 227 Th/ 223 Ra, 225 Ac, 211 At, and 212 Pb/ 212 Bi)
-
the α-emitting radionuclide that is perhaps easiest to produce. However, its availability has been limited because there are few accelerators in the world
-
the limited availability and high cost of high-activity generators are presently hampering further studies
-
The current generator is sufficient only for preclinical development (not clinical use)
-
For most TAT radionuclides, current demand significantly exceeds the available supply
-
clinical studies mainly focusing on the treatment of prostate cancer, neuroendocrine tumors, and gliomas
-
- 2
Bristol Myers Squibb, 2024. Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform .
The purchase price of RayzeBio and its lead actinium-225 drug candidate. Read with Firecrawl.
-
A Phase 3 clinical trial is currently enrolling patients to evaluate RYZ101 in patients with SSTR-positive GEP-NETs
-
- 3
The Phase 3 trial of actinium-225-PSMA-617, start date and status.
-
This is a phase III, open label, multicenter randomized study. … Start Date Jul 01, 2025
-
PSMA-positive Metastatic Castration Resistant Prostate Cancer
-
- 4
US Department of Energy, Office of Science, Isotope R&D and Production, 2019. Improving Isotope Supply for a Cancer-Fighting Drug .
Actinium-227 made at Oak Ridge from recovered radium-226 for Bayer's radium-223 drug, under a 10-year contract.
-
After the Food and Drug Administration approved this new drug to treat prostate cancer in 2013
-
- 5
Shannon Brescher Shea, US Department of Energy, Office of Science, 2018. The Journey of Actinium-225: How Scientists Discovered a New Way to Produce a Rare Medical Radioisotope .
History of actinium-225 at Oak Ridge, the accelerator route, demand estimate, why alpha emitters treat cancer.
-
This energy is so high that it can break bonds in DNA. This damage can destroy cancer cells’ ability to repair and multiply, even killing off tumors.
-
Neither too long nor too short, 10 days is just right for some cancer treatments. The relatively short half-life limits how much it accumulates in people’s bodies. At the same time, it gives doctors enough time to prepare, administer, and wait for the drug to reach the cancer cells
-
demand for actinium-225 could rise to more than 50,000 millicuries (mCi, a unit of measurement for radioactive isotopes) a year. The current process can only create two to four percent of that amount annually.
-
- 6
Kratochwil C. et al., Journal of Nuclear Medicine 57(12), 2016. 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer .
The first patients treated with actinium-225-PSMA-617 in Heidelberg, and why some patients need an alternative to lutetium-177.
-
Recently, we started the first-in-human treatment with an α-radionuclide–labeled PSMA ligand. Although the case series is still ongoing, we here report in advance about two patients
-
about 30% of patients do not respond to 177 Lu-labeled PSMA ligands
-
- 7
Cathy S. Cutler (Brookhaven National Laboratory) and Dan Stracener (Oak Ridge National Laboratory), US DOE Isotope Program, 2022. Ac-225 DOE Isotope Program User Group Meeting , Slides 6 to 8.
World supply from thorium-229 generators, Oak Ridge output, doses per patient, expected yields of accelerator targets.
-
Projection of 225Ac demand assuming multiple, approved 225Ac and 213Bi drugs and robust clinical R&D programs could be in the hundreds of Ci/year
-
2008 Workshop on The Nation’s Needs for Isotopes
-
(160-640 µCi/patient)
-
- 8
World Nuclear News, 2019. Partnership to produce medical isotope from legacy waste .
The 2019 agreement between Isotek, TerraPower and the US DOE on thorium-229 from uranium-233.
-
This arrangement will give TerraPower the capacity to produce 100 times more cancer treatment doses per year of Ac-225 than the 4000 doses currently available, the partners said.
-
- 9
Richard Zimmermann (Chrysalium Consulting, MEDraysintell), editorial in the Journal of Nuclear Medicine 64(10), 2023. Is Actinium Really Happening? .
A consultant's forecast of world capacity for actinium-225 by 2032, the five production routes, and the waste question of actinium-227. Read with a script and saved; Table 1 (capacity by site) read in a browser and added.
-
the worldwide 225 Ac production capacity by 2032, estimated largely above 25 TBq (670 Ci), should be sufficient to produce at least 2 million patient doses a year
-
The first 225 Ac-labeled molecule has entered the clinical phase III stage ( 2 ) and might reach the market by 2028.
-